Hyzaar

Losartan potassium and hydrochlorothiazide, the active ingredients in Hyzaar, are an angiotensin II receptor blocker and a thiazide diuretic presented as a tablet for oral use. It treats hypertension in adult patients. GNH USA supplies Hyzaar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Hyzaar combines an angiotensin II receptor blocker with a thiazide diuretic to manage high blood pressure.

- Essential hypertension: lowers systolic and diastolic pressure in adult patients. - Hypertension with fluid retention: provides diuretic action to reduce plasma volume. - Hypertension requiring combination therapy: offers dual mechanisms to improve blood pressure control.

Common Side Effects: - Dizziness: feeling light‑headed, especially after standing. - Headache: mild to moderate intensity. - Fatigue: general tiredness or lack of energy. - Increased urination: due to the diuretic component. - Muscle cramps: occasional leg or calf cramps. - Nausea: mild stomach upset.

Serious or Rare Side Effects: - Severe dehydration: marked fluid loss requiring medical attention. - Hyperkalemia: elevated potassium levels that can affect heart rhythm. - Acute kidney injury: sudden decline in renal function. - Angioedema: swelling of face, lips, tongue, or throat. - Severe hypotension: dangerously low blood pressure. - Allergic reactions: rash, itching, or anaphylaxis.

Before initiating Hyzaar, consider the following precautions. - Monitor blood pressure: ensure adequate control and avoid excessive lowering. - Check electrolytes: especially potassium and sodium levels. - Avoid in pregnancy: drug is classified as Category D and may harm the fetus. - Use caution in renal impairment: dose adjustment may be required. - Do not discontinue abruptly: taper under medical supervision. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Hyzaar may interact with several medicines; review the following.

Major Interactions (Avoid): - Aliskiren (in diabetes): increased risk of renal dysfunction. - Potassium‑sparing diuretics: risk of hyperkalemia. - NSAIDs: may reduce antihypertensive effect. - Lithium: increased lithium toxicity. - ACE inhibitors or other ARBs: additive potassium elevation.

Moderate Interactions (Monitor Closely): - Other antihypertensives: additive blood pressure lowering. - Loop diuretics: monitor electrolyte balance. - Antidiabetic agents: possible enhanced hypoglycemia. - CYP2C9 inhibitors (e.g., fluconazole): may increase losartan levels. - Antacids containing aluminum or magnesium: may affect absorption.